104 Use of the eShunt Implant in Treatment of Aneurysmal Subarachnoid Hemorrhage Communicating Hydrocephalus

Pedro Lylyk,Ivan Lylyk,Carlos Bleise,Esteban Scrivano,Nicholas Pedro Lylyk,Brandon Beneduce,Carl B. Heilman,Adel M. Malek
DOI: https://doi.org/10.1227/neu.0000000000002809_104
IF: 5.315
2024-04-01
Neurosurgery
Abstract:INTRODUCTION: Aneurysmal subarachnoid hemorrhage (aSAH) may cause communicating hydrocephalus and elevated intracranial pressure (ICP) not amenable to weaning of cerebrospinal fluid (CSF) external ventricular drainage (EVD), often requiring surgical ventriculoperitoneal shunting (VPS) with risk of hemorrhage and infection. METHODS: Patients having intractable elevated ICP with EVD clamping and favorable inferior petrosal sinus and bony anatomy were included. ICP was monitored before and after eShunt deployment for 36-48 hours. Primary endpoint was reached if ICP remained <20 cmH2O enabling EVD removal. CT imaging of the brain was obtained immediately post-eShunt placement to evaluate eShunt placement and assess for any presence of new procedural hemorrhage. RESULTS: Seven out of eight patients (5 female; age 64 ± 12 years) underwent successful transfemoral transvenous eShunt procedure at 25.3 days (Range 14-38) post aSAH. Primary endpoint was achieved in all with EVD removal by 36-48 hours without procedural or delayed hemorrhage. Mean ICP rapidly decreased from 33.4 to 13 cmH2O at 1 hour (p < 0.0001) and to 9 cmH2O (p < 0.0001) at 36 hours post eShunt placement. CONCLUSIONS: These early encouraging results of the eShunt implant suggest clinical role and utility in the management of subarachnoid hemorrhage associated hydrocephalus possibly eschewing the need for VP shunt surgery and enabling minimally invasive CSF diversion in patients requiring dual anti-platelet or anticoagulant therapy.
surgery,clinical neurology
What problem does this paper attempt to address?